ICIs are the most thoroughly investigated and critically important immunotherapeutic agents, and the clinical application of PD-1 or PD-L1 and CTLA-4 inhibitors has improved the OS of various patients with cancer (Riley et al. 2019). This evidence concerns the gene PDCD1 and cancer.